The evolving place of incretin-based therapies in type 2 diabetes

Medizinische Klinik IV, Otfried-Müller-Strasse 10, 72076, Tübingen, Germany.
Pediatric Nephrology (Impact Factor: 2.86). 07/2010; 25(7):1207-17. DOI: 10.1007/s00467-009-1435-z
Source: PubMed


Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005. These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In adult medicine, both treatment options are attractive and more commonly used because of their action and safety profile. The incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia. GLP-1 receptor agonists allow weight loss, whereas DPP-4 inhibitors are weight neutral. This review gives an overview of the mechanism of action and the substances and clinical data available.

Download full-text


Available from: Baptist Gallwitz
  • Source
    • "The resulting agonists and antagonists have increased metabolic stability, biological activity, and bioavailability. For example, the energy metabolism-regulating hormone Glp1 is highly unstable with a bioavailability of only 1–2 min due to its rapid enzymatic degradation by dipeptidyl peptidase 4. In contrast, the N-acylated Glp1 analog Liraglutide has a half life of 14 h, which makes it suitable for the treatment of type 2 diabetes73. Exenatide, an analog of the naturally occurring Glp1 agonist Exendin-4, in which the second alanine is substituted by serine, improves both stability and activity73. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Class B G-protein-coupled receptors (GPCRs) are receptors for peptide hormones that include glucagon, parathyroid hormone, and calcitonin. These receptors are involved in a wide spectrum of physiological activities, from metabolic regulation and stress control to development and maintenance of the skeletal system. As such, they are important drug targets for the treatment of diabetes, osteoporosis, and stress related disorders. Class B GPCRs are organized into two modular domains: an extracellular domain (ECD) and a helical bundle that contains seven transmembrane helices (TM domain). The ECD is responsible for the high affinity and specificity of hormone binding, and the TM domain is required for receptor activation and signal coupling to downstream G-proteins. Although the structure of the full-length receptor remains unknown, the ECD structures have been well characterized for a number of Class B GPCRs, revealing a common fold for ligand recognition. This review summarizes the general structural principles that guide hormone binding by Class B ECDs and their implications in the design of peptide hormone analogs for therapeutic purposes.
    Full-text · Article · Mar 2012 · Acta Pharmacologica Sinica
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite availability of several oral hypoglycemic agents, safe and effective treatment still represents a challenge in type 2 diabetes (T2DM) and a large percentage of patients do not reach the therapeutic goal of a near normal HbA1c value. Incretin-based therapies represent a relatively new treatment approach that may address some of the shortfalls of the traditional treatments. ''Incretins'' are hormones secreted by the gastrointestinal tract upon food intake. Glucagone like peptide-1 (GLP-1), the first incretin to be described, potentiates glucose-dependent insulin secretion and appears capable, at least in vitro and in animal models, to preserve beta-cell mass and function. Due to its characteristics, GLP-1 is considered a very attractive molecule for treatment of type 2 diabetes. However, native GLP-1 is rapidly degraded by the enzyme dipeptidyl-peptidase IV (DPP-4) and, therefore, it is not suitable for clinical use. This has led to development of the two classes of incretin-based drugs that are presently approved for type 2 diabetes treatment: DPP-4 inhibitors (or incretin enhancers) that are small compounds readily absorbable when assumed orally, which will prolong endogenous GLP-1 half-life and GLP-1-receptor agonists (or GLP-1 mimetics), which are injectable molecule mimicking endogenous GLP-1 action but with a longer half-life. Efficacy, safety, and clinical use of the available compounds of these two classes are discussed in this review. It is concluded that, on the basis of the available evidence, incretin-based therapies do represent a very flexible tool to achieve optimal blood glucose control in type 2 diabetic patients.
    Full-text · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MKC253 is glucagon-like peptide 1 (GLP-1, 7-36 amide) adsorbed onto Technosphere microparticles for oral inhalation. The pharmacokinetics of inhaled GLP-1 and the pharmacokinetic-pharmacodynamic (PK-PD) relationship between inhaled GLP-1 and insulin were analyzed in two trials, one in healthy normal volunteers and the other in patients with type 2 diabetes. Inhaled GLP-1 was absorbed quickly, with peak concentrations occurring within 5 min, and levels returned to baseline within 30 min. Inhaled GLP-1 appeared to produce plasma levels of GLP-1 comparable to those of parenteral administration and sufficient to induce insulin secretion resulting in attenuation of postmeal glucose excursions in subjects with type 2 diabetes. An E(max) (maximum effect) model described the relationship between GLP-1 concentration and insulin release. The variability in the E(max) may be due to differences in baseline glucose levels, differences resulting from genetic polymorphisms in GLP-1 receptors (GLP-1Rs), or the stage of diabetes of the patient.
    Full-text · Article · Aug 2010 · Clinical Pharmacology &#38 Therapeutics
Show more